Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O43151

UPID:
TET3_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
O43151; A6NEI3; J3KNF3; K9JJH7; Q86Z24; Q8TBM9

BACKGROUND:
The enzyme Methylcytosine dioxygenase TET3 is central to DNA demethylation processes, transforming 5-methylcytosine into forms that facilitate epigenetic reprogramming. Its activity is crucial in early zygotic stages, affecting gene expression regulation and developmental pathways by modulating DNA methylation patterns.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Methylcytosine dioxygenase TET3 could open doors to potential therapeutic strategies, especially considering its link to Beck-Fahrner syndrome, which encompasses a range of intellectual and developmental challenges.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.